A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients With Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Phase of Trial: Phase III
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms PROSPER RCC
- 10 Feb 2018 Trial design presented at the 2018 Genitourinary Cancers Symposium
- 11 Jan 2018 Planned End Date changed from 31 Jul 2022 to 30 Nov 2023.
- 11 Jan 2018 Planned primary completion date changed from 31 Jul 2022 to 30 Nov 2023.